ELI LILLY WKN: 858560 ISIN: US5324571083 Forum: Aktien Thema: Hauptdiskussion

Buy in now

All in now

Falsches Forum?

Die Hersteller von Abnehmmitteln Novo Nordisk und Eli Lilly erhalten während der Anhörung von RFK Jr. Unterstützung, der die Medikamente als Wundermittel bezeichnet und ihnen eine Daseinsberechtigung zuspricht. Stock3

HEINEKEN HOLDING!

Erstaunlich für das Gemetzel heute Lilly hält sich gut... Earning-Vorlauf

https://x.com/faststocknewss/status/1884322473375850530?t=M-udPSODmy9vjWtuequJIw&s=19

FDA APPROVES OZEMPIC (SEMAGLUTIDE) AS THE ONLY GLP-1 RA TO REDUCE THE RISK OF WORSENING KIDNEY DISEASE AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE $NVO $LLY

https://stock3.com/news/novo-nordisk-meldet-studienerfolg-aktie-steigt-8-16076316

Novo Nord. + 9 % ?!....

Morgan Stanley skizziert drei mögliche Szenarien im Rechtsstreit zwischen Compounding-Apotheken und der FDA über die Herstellung von Tirzepatide, wobei eine vorläufige Gerichtsentscheidung bis Anfang April erwartet wird. Die Klage der Compounding-Gruppen richtet sich gegen die Entfernung von Eli Lillys Diabetes-Medikament Tirzepatide von der FDA-Mangelliste, wobei der Fall auch Auswirkungen auf Novo Nordisks Semaglutide haben könnte. Stock3

Neue Studiendekan

Novo geht 8% hoch.

Was geht nun wieder……typischer Freitag

'Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.'

The study, published in Nature Medicine, showed that patients treated with GLP-1 medications were 12% less likely to develop Alzheimer’s. An Oxford University study in July last year also showed Novo’s GLP-1 medicine reduced the risk for dementia when compared with another Type 2 diabetes medicine, Merck’s Januvia. The most known GLP-1 drugs, and the only ones currently approved for weight management, are Novo’s Semaglutide and Lilly’s Tirzepatide. Semaglutide, which is sold as Ozempic for diabetes and Wegovy for weight-loss has already been approved for treating cardiovascular conditions and kidney disease while Tirzepatide, sold under Mounjaro for diabetes and Zepbound for weight-loss, is approved for treating sleep apnea. The new study was also associated with reduced risk for substance abuse, psychotic disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. On the flip side, the researchers found an increased risk of conditions including gastrointestinal disorders, hypotension and kidney and pancreatic disorders. The study looked at a large number of U.S. veterans with diabetes over six years, therefore data is likely to be skewed to senior white males. https://www.marketwatch.com/articles/novo-lilly-stock-weight-loss-drugs-alzheimers-57496e0a?mod=mw_quote_news